chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial report received from a consumer on 21 Jan 2010: This patient with no prior history of cardiovascular symptoms was vaccinated with S-OIV Flivirin (Influenza virus vaccine A H1N1) on 19 Jan 2010. The patient reported that after 1 hour of vaccination, her heart stopped. The patient was taken to hospital and stayed overnight. The patient also experienced itchy strawberry rash on arms on 19 Jan 2010 after vaccination. The patient did not experience any cardiovascular symptoms prior to receiving the vaccine. The patient discharged from the hospital. Final outcome of the events was not reported.
received 2 doses years ago and a dose in Nov 9th; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 20-year-old male patient who received HBV (Engerix B) (batch number 25K4M, expiry date 2nd June 2024) for prophylaxis.   Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Engerix B (in 2015 or 2016, patient had received 2 doses of the same vaccine).   On 9th November 2022, the patient received the 3rd dose of Engerix B and Engerix B Pre-Filled Syringe Device. On 9th November 2022, unknown after receiving Engerix B and Engerix B Pre-Filled Syringe Device, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 23-FEB-2023 Reporter's comments: Patient mentioned that in 2015 or 2016 received 2 doses of the same vaccine but did not finish the schedule either. Pharmacist reported that Engerix B was administered on 9th November (year not mentioned) and patient did not comeback for the another dose until today (Feb 23rd 2023). The reporter consented to follow up. Additional supportive information: The patient had received the third dose later than the recommended interval, which had led to lengthening of vaccination schedule. Based on the structured field date, the vaccination date was captured conservatively and AI was raised to confirm the same.
1st dose of shingrix on April 7, 2019 and 2nd dose on August 9, 2019 / Got attack of shingles in November 2020/ suspected vaccination failure; shingles; This case was reported by a physician via sales rep and described the occurrence of suspected vaccination failure in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 9th August 2019, the patient received the 2nd dose of Shingrix. On 7th April 2019, the patient received the 1st dose of Shingrix. In November 2020, between 1 and 2 years after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received 2 doses of vaccine and got attack of shingles in November 2020. This case was considered as suspected vaccination failure as details regarding laboratory confirmation were unknown at the time of reporting. The reporter consented to follow up.
About a week after the first dose my small fiber neuropathy pain became greatly exacerbated and more widespread
I just recently found out that my health care provider did not submit the VAERS report at the time the vaccine was administered and I reported the problems to the clinic. It is my fundamental belief that this information should have been reported, and is the reason I am doing so at this late date. From what I remember about an hour after the vaccine was administered, a headache started and lasted about 24 hours. (Generally not prone to headaches.) At about 3:00 am the following morning, I awoke and spent some time in the bathroom throwing up. Only once occurrence of this. At the same time this was going on, I started itching on left shoulder. Realized that where I was scratching was caused a raised surface on my skin where I was touching it. This was later diagnoses as dermagraphia. As the headache was disappearing, numbness and a tingling sensation took over. As the numbness and tingling sensations resolve, joint related pain become obvious for an extended period of time. Have gone several rounds with this. Still has not completely resolved. Recently diagnoses as polyneuropathy. At about a week, started have joint pain very similar to what is described in the VIS. Moved through various places. Both wrists, both hips, left knee and most finger joints. Took less than a week to travel through the areas. This is tough to explain both there did seem to be a difference between the joint pain that develops after about with the numbness and tingling versus what started about 6 days in to this. May have experienced inflammation in the finger joints. (Pink coloration, warm to touch). Started with the VIS-type joint pain, and lasted about 6 to 7 weeks.
Rash on left side of face Feels warm but not painful Clustered vesicles left cheek and ear
Red spot after 7 days; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Red spot after 7 days) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history provided).    On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Red spot after 7 days). At the time of the report, VACCINATION SITE ERYTHEMA (Red spot after 7 days) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       no concomitant medication provided no treatment provided
4/12/21 immediately following the vaccine it felt like I had a ?dead arm?. I had radiating pain in my arm and down to my fingers. I did get really sick after from the side effects but when that went away the pain in my left arm stayed.
Information has been received from a pharmacist concerning a 65 year old female consumer with codeine and sulfonamide allergies and no pertinent medical history who on 02-APR-2008 was vaccinated SQ with zoster vaccine live (Oka/Merck) (lot # 659762/1874U). Concomitant therapy included RELAFEN, LUMIGAN and LEVOXYL. On 02-APR-2008, the patient broke her tooth after receiving the vaccine. Medical attention was sought via the telephone. There were no lab studies performed. At the time of the report the patient was recovering. There was no product complaint involved. Additional information has been requested.
Resident was in observation area. Noted to by lying across husband's lap. Resident was taken to EMS room & threw up. Given ice pack, snack & water. Afterwards voicing relief. Vitals BP 122/78, HR73, 99% RA, RR 18. At 1830 denied being lightheaded or dizzy, refused wheelchair & walked out with husband was asymptomatic
18Apr90 pt vax;  exp low grade fever & rash.  Noted to have abnormal eye movement.  Dx of sixth nerve palsy made.  Tx w/ rx drug.  Remained under tx.
could not swallow anything; jaw swelled; her throat swelled up; This spontaneous report was received from a female patient of unknown age who reported on herself via other company. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.     On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (exact dose, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis.  On an unknown date, 2-3 weeks after taking the vaccine, her throat swelled up and jaw swelled, she could breath but could not swallow anything and had to go to Emergency Room (ER). The outcome of the events was unknown. It was also reported that she was getting ready to get her COVID vaccine pretty soon but wanted to know about anything common in COVID vaccine and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II).  Causality assessment was not provided.
Tansverse myelitis; A spontaneous report  was received from a physician, who was also a 50-year-old male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced transverse myelitis.  The patient's medical history included cervical disc disease and low testosterone.  Concomitant medications included testosterone cypionate and anastrozole.  The patient reported that he had no acute illnesses at the time of vaccination and up to one month before.  He had no allergies to medications, food, or other products.  On 30 Dec 2020 at 12:00 pm, the patient received their first of two planned doses of mRNA-1273 (Lot number: 011J20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection.  On or about 07 Jan 2021, the patient began experiencing numbness in both feet.  Thinking it could be related to his prior cervical disc disease causing myelopathic symptoms, hence, the patient saw a spine surgeon, who ordered a cervical magnetic resonance image (MRI) which revealed of no acute changes. On or about 18 Jan 2021, the patient began having problems with leg weakness and difficulty in standing and walking.  That same day, he underwent urgent MRIs of his thoracic and lumbar spines which showed a lesion on the anterior thoracic cord.  The patient was referred to a neurologist who diagnosed the patient with transverse myelitis.  Subsequently, follow-up MRIs with contrast, MRI of the brain, and lumbar puncture for CSF analysis were completed but no other causes of his symptoms were identified.  At the time of this report, the patient's legs were always numb (numbness propagated proximally with activity), his legs were weak, gait was unstable, he noted sexual dysfunction, and he had frequent "electrical" sensations.  A follow-up thoracic MRI was completed on 05 Feb 2021 (results pending at time of this report).    Treatment for the event included intravenous immunoglobulin (IVIG) infusions for five days (to start on 06 Jan 2021).    The action taken with mRNA-1273 in response to the event was withdrawn (regarding dose two, the patient reported: "N/A not given").  The event, transverse myelitis, was considered not resolved at the time of this report.  The physician assessed the event of transverse myelitis as related to mRNA-1273.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  However, it is noted that follow-up MRIs with contrast, MRI of the brain, and lumbar puncture for CSF analysis were completed and no other causes of his symptoms were identified but confirmation of the event was not reported.  Also, the patient's comorbidities (cervical disc disease and low testosterone) may contribute to the patient's symptoms and confounds causality assessment. Further information has been requested.
Drenching sweat, shaking chills, coughing & sore throat. All symptoms resolved by the following morning.
Lymph nodes in left armpit swollen to grapefruit size; This is a spontaneous report from a contactable consumer. A 43-year-old non pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: Unknown), dose 2 via an unspecified route of administration on 13Feb2021 at 08:45 (at the age of 43-year-old) as 2ND DOSE, SINGLE in left arm for COVID-19 immunization. The patient's medical history included a known allergies of Peas, apples, pork. Patient was not pregnant at the time of vaccination. Concomitant medications included Zoloft. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: Unknown) via an unspecified route of administration on 23Jan2021 at 10:30 AM (at the age of 43-year-old) as single dose in left arm for COVID-19 immunization. On 14Feb2021, the patient's lymph nodes in left armpit swollen to grapefruit size, making it difficult to use that arm/shoulder. The patient did not receive any treatment for the event. The patient had no COVID prior vaccination and was not tested COVID post vaccination. The clinical outcome of the event was not recovered.  Information on the lot/batch number has been requested.  Follow-up attempts are completed. No further information is expected.
vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications are provided.  No treatment medications are provided.  Patient did not experience any other adverse reactions.   This case was linked to MOD-2021-395985 (Patient Link).
Injection site became very red, swollen, hot to the touch and soreness returned 10 days after vaccination.  Called my healthcare provider and he prescribed Cephalexin 500 MG  to be taken three times a day for seven days.  Three days after starting antibiotic treatment, redness and swelling were gone along with the fever in the arm.  Healthcare provider suggested I not take the second dose.  I would like an opinion from your facility.
SIDE EFFECTS; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 02-APR-2021 for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On 02-APR-2021, the subject experienced side effects. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from side effects on 03-APR-2021. This report was non-serious.
I woke up in the morning with a fever, heaviness in my chest. I thought I was having a heart attack; I had my wife take me to the emergency room. Upon entering the emergency room, they hooked me up to an EKG, ran a CBC bloodwork, chest x-ray, CT scan. The bloodwork came back showing my enzymes were normal no heart attack detected, my EKG was normal, the chest x-ray and CT scan showed that I had pneumonitis, cardiomegaly, and possible pleurisy. I have a follow up visit with a cardiologist.
slept entire day next day; difficult to move; needed help to use bathroom/ and reports it is very isolating, because she cannot meet friends, go to a restaurant, and she will not go to anyone's house.; severe muscle pain; severe joint pain; arm killed her; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSOMNIA (slept entire day next day), GAIT DISTURBANCE (difficult to move), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (needed help to use bathroom/ and reports it is very isolating, because she cannot meet friends, go to a restaurant, and she will not go to anyone's house.), MYALGIA (severe muscle pain) and ARTHRALGIA (severe joint pain) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Respiratory syncytial virus infection NOS. Concomitant products included OCRELIZUMAB (OCREVUS) for an unknown indication.    On 14-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERSOMNIA (slept entire day next day), GAIT DISTURBANCE (difficult to move), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (needed help to use bathroom/ and reports it is very isolating, because she cannot meet friends, go to a restaurant, and she will not go to anyone's house.), MYALGIA (severe muscle pain), ARTHRALGIA (severe joint pain) and VACCINATION SITE PAIN (arm killed her). At the time of the report, HYPERSOMNIA (slept entire day next day), GAIT DISTURBANCE (difficult to move), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (needed help to use bathroom/ and reports it is very isolating, because she cannot meet friends, go to a restaurant, and she will not go to anyone's house.), MYALGIA (severe muscle pain), ARTHRALGIA (severe joint pain) and VACCINATION SITE PAIN (arm killed her) outcome was unknown.            No Concomitant medication was reported.   On 01Oct2021, she had her blood drawn for an antibody test. She reports she has no antibodies, despite taking 3 doses of the vaccine. She was scared to take the third dose. She reports her spike AB was negative, and SARS test was negative.   No treatment medication was reported.   This case was linked to MOD-2021-302110, MOD-2021-302102 (Patient Link).
09/18/22 presents to ED for "fever, fatigue". PMHx of " HTN, HLD, DM, CLL on plavix"
Three days after first shot I developed purple raised spots on my face which passed after 2-3 weeks.   4 days after second shot started having trouble with lower heart rate, went to ER when it fell to 37.  Since then have been in and out of doctors offices, ER, hospitalization, and dealing with mix of symptoms.  Exhaustion/fatigue, sweats, lower heart rate, near fainting, brain fog, pressure or pain in heart area, dizziness, light headed ness.
p/vax pt exp lt arm redness & swelling; warm to touch; allegra po; ice to inj; recovery pending
Pt went to PCP w/ red, swollen, and heat at site of administration. Pt also reported having redness & pain surrounding site of administration. PCP stated pt had redness approximately 17 cm in diameter surrounding area & diagnosed pt w/ cellulitis. Pt has been started on KEFLEX 500mg 1 PO TID x 7 days. Pt is being seen by PCP in 7 days for follow-up.
Patient presented to the emergency department on 11/12/2021 with shortness of breath and nonproductive cough. He had taken a home test that showed he was positive for COVID-19. He deferred monoclonal antibodies at that time and was discharged home. Patient presented to emergency department again on 11/13/2021 with shortness of breath and hypoxia. He was admitted for further management on his COVID-19 infection. He was treated with dexamethasone, remdesivir, and supplemental oxygen. He was discharged home on 11/19/2021. Patient presented to a different health system on 11/20/2021 with GI bleed and expired on 11/20/2021.
N93.9 - Abnormal uterine and vaginal bleeding, unspecified unknown if pregnant please request additional information for a chart review if needed
varicella-like rash 10 days p/vax;no fever, dec oral intake, itching;red papules chest, arms, legs, face, scalp;no confluence;no vesicles;
On 4/24/2021 developed COVID-19 symptoms.    Cough, diarrhea, headache, nasal congestion.  Tested positive by PCR.
Sick feeling ,  tired, 100.4 temperature, headache,  muscle aches in legs and small of the spine,  had to stay in bed 13,14th and am up today the 15th but still feeling tired.
Pt recvd MMR 20May.On 30May had T of 105-called MD gave APAP & T went down to 101 for 4 hrs then down to 99.No fever the next day-no rash or other sxs noted
Initial report was received from a healthcare professional on 05 December 2012. An 82-year-old male patient had received an injection of FLUZONE High-Dose (lot number, route, site and date of administration not reported) and one day later experienced severe chills and shakes. The patient laid down on the floor, was unable to get up and needed assistance. The office directed the patient to go to the hospital but the patient did not go. The patient was unable to move for two days. The patient "was paralyzed for two days". Outcome was not reported. Documents held by sender: None.
Chills, body aches, headache, & fatigue. I had COVID-19 in early December and these symptoms are very similar.
I noticed a scaly, dry spot on the back of my thigh sometime between 4/6/21 and 4/9/21. I didn't think much of it until roughly 4/21/21, when the rash spread across my body. It is primarily on my torso (front and back) but also on legs, arms, and face. The rash was originally red and scaly, and is beginning to fade so it has less texture. Most spots are about nickel sized, but some are closer to an egg. It is not itchy or painful, just very dry and red. I had my second dose of the Pfizer vaccine yesterday which is what prompted me to realize it was probably a side effect of the shot - because it did not come on until about 2 weeks later, I didn't originally put the two together. I will be watching to see if it worsens in another week or two now that I've had the second dose. I have scheduled an appointment with my primary care doctor to be safe.
She reports having an allergic reaction to a supplement; This is a spontaneous report from Pfizer Sponsored Program.  A contactable female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID19 VACCINE, Solution for injection, Lot number was not reported), dose 1st via an unspecified route of administration on an unspecified date as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Patient had an allergic reaction to a supplement. She wanted to know if she can take prednisone to treat that reaction, she was concerned by the possible effect of prednisone on her vaccine doses. she scheduled for her second dose of the Pfizer-Biontech Covid19 vaccine on 02May2021. The Outcome of the event was unknown.     No follow-up attempts are possible. No further information is expected.